Interferons

17 trials

Sponsors

Center for Genetic Engineering and Biotechnology (CIGB), Center for Genetic Engineering and Biothecnology (CIGB), in Havana., Center for Genetic Engineering and Biotechnology (CIGB), in Havana, National Center for Scientific Research (CNIC)

Conditions

Acuminate CondylomaAcute respiratory infection (ARI)COVID-19 COVID-19 SARS-CoV-2COVID-19 COVID-19 SARS-CoV2Chronic Myeloid Leukemia.Covid 19 COVID-19KeloidsNone. Healthy volunteers.

Phase 1

Active, not recruitingRPCEC00000039

Center for Genetic Engineering and Biotechnology (CIGB)None. Healthy volunteers.

Start: 2007-05-20Target: 16Updated: 2026-03-30

Active, not recruitingRPCEC00000052

Center for Genetic Engineering and Biotechnology (CIGB)Skin basal cell carcinoma, Squamous cells carcinoma.

Start: 2002-08-05Target: 21Updated: 2026-03-30

Pharmacodynamics of the Nasalferon in healthy volunteers.

Active, not recruitingRPCEC00000308

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaPharmacodynamics and safety in healthy volunteers pharmacodynamics

Start: 2020-05-04Target: 30Updated: 2026-03-30

Phase 2

Active, not recruitingRPCEC00000038

Center for Genetic Engineering and Biotechnology (CIGB)Acuminate Condyloma

Start: 2003-04-22Target: 30Updated: 2026-03-30

Application of CIGB-128 in keloid patients undergoing surgical exeresis.

Active, not recruitingRPCEC00000061

Center for Genetic Engineering and Biotechnology (CIGB)Keloids

Start: 2004-04-02Target: 45Updated: 2026-03-30

CIGB-128 administration to patients with surgically-treated keloids.

RecruitingRPCEC00000062

Center for Genetic Engineering and Biotechnology (CIGB)Keloids

Start: 2003-11-13Target: 30Updated: 2026-03-30

Active, not recruitingRPCEC00000066

Center for Genetic Engineering and Biotechnology (CIGB)Skin basal cell carcinoma (BCC)

Start: 2001-03-26Target: 60Updated: 2026-03-30

HEBERFERON in renal cell carcinoma

Active, not recruitingRPCEC00000229

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaRenal Cell Carcinoma state III and IV after nefrectomy

Start: 2017-03-03Target: 270Updated: 2026-03-30

ESPERANZA study

RecruitingRPCEC00000307

Center for Genetic Engineering and Biotechnology (CIGB), in Havanapatients infected with the SARS-CoV-2 coronavirus. covid-19

Start: 2020-04-10Target: 120Updated: 2026-03-30

Active, not recruitingRPCEC00000337

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaProphylaxis of SARS-CoV-2 infection COVID-19 SARS-CoV2

Start: 2020-10-12Target: 80Updated: 2026-03-30

Phase 3

Rectal ozone therapy in high-risk symptomatic SARS-CoV-2 positive patients

Active, not recruitingRPCEC00000383

National Center for Scientific Research (CNIC)COVID-19 COVID-19 SARS-CoV2

Start: 2021-09-01Target: 292Updated: 2026-03-30

Nasalferon in COVID-19

Active, not recruitingRPCEC00000399

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-22Target: 128Updated: 2026-03-30

Nasalferon in ARI

Active, not recruitingRPCEC00000407

Center for Genetic Engineering and Biotechnology (CIGB)Acute respiratory infection (ARI)

Start: 2022-09-01Target: 495Updated: 2026-03-30

Nasal recombinant human interferon alfa-2b in ARI

Active, not recruitingRPCEC00000412

Center for Genetic Engineering and Biotechnology (CIGB)acute respiratory infection

Start: 2023-02-01Target: 608Updated: 2026-03-30

Phase 4

Active, not recruitingRPCEC00000050

Center for Genetic Engineering and Biothecnology (CIGB), in Havana.Chronic Myeloid Leukemia.

Start: 1999-07-16Target: 60Updated: 2026-03-30

Unknown Phase

Rectal Ozone in the COVID-19 treatment

Active, not recruitingRPCEC00000320

National Center for Scientific Research (CNIC)Covid 19 COVID-19

Start: 2020-06-08Target: 32Updated: 2026-03-30

Expanded Clinical Use of Nasalferon in COVID-19

Active, not recruitingRPCEC00000396

Center for Genetic Engineering and Biotechnology (CIGB)COVID-19 COVID-19 SARS-CoV-2

Start: 2021-11-15Target: 200Updated: 2026-03-30

Related Papers

Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

2009-07-3012 citations